Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Mol Carcinog. 2012 Oct 12;53(3):230–242. doi: 10.1002/mc.21969

Figure 4. Decreased neuroblastoma cell viability with siRNA inhibition of vascular endothelial growth factor receptor-3 (VEGFR-3).

Figure 4

A. VEGFR-3 siRNA (0.14 µM) transfection for 48 hours resulted in decreased VEGFR-3 expression in SK-N-AS neuroblastoma cells compared to control siRNA (top panel). Densitometry was used to further show the differences (bottom panel) with VEGFR-3 expression normalized to β-actin and reported as a fold change from cells with no treatment. B. The same RNAi treatment of the SK-N-BE(2) cell line resulted in a decrease in VEGFR-3 expression compared to control siRNA (top panel). Densitometry was used to further show the differences (bottom panel) with VEGFR-3 expression normalized to β-actin and reported as a fold change from cells with no treatment. C. Cell viability was detected with MTT assay. Viability of SK-N-AS cells was significantly decreased with 48 hours of siRNA inhibition of VEGFR-3 (left panel). Treatment of SK-N-BE(2) cells with VEGFR-3 siRNA for 48 hours also significantly decreased viability in these cells (right panel).